Drug Search Results
More Filters [+]

Revefenacin

Alternative Names: revefenacin, td-4208, gsk1160724, yupelri
Latest Update: 2024-08-27
Latest Update Note: News Article

Product Description

Revefenacin, a once-daily long-acting muscarinic antagonist for nebulization recently approved by the US FDA for the treatment of patients with COPD, was discovered and developed using "duration and lung selectivity-by-design." This strategy selected a molecule with a high lung-selective index to maximize bronchodilation and limit systemic anti-muscarinic side effects.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31908443/)

Mechanisms of Action: mAChR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Inhalant,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Egypt | Lebanon | Philippines | Saudi Arabia | Singapore | United Arab Emirates | United States

Approved Indications: Chronic Obstructive Pulmonary Disease

Known Adverse Events: Back Pain | Headache | Pain Unspecified | Nasopharyngitis | Pharyngitis | Respiratory Tract Infections

Company: VIATRIS & KG
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Revefenacin

Countries in Clinic: China, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Chronic Obstructive Pulmonary Disease

Phase 2: Respiratory Insufficiency

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RARICO

P2

Recruiting

Respiratory Insufficiency|Chronic Obstructive Pulmonary Disease

2024-06-01

REV-3001

P3

Completed

Chronic Obstructive Pulmonary Disease

2023-07-26

92%

CTR20202111

P1

Not yet recruiting

Chronic Obstructive Pulmonary Disease

None

CTR20212308

P3

Not yet recruiting

Chronic Obstructive Pulmonary Disease

None

Recent News Events